AI-generated summary
The authors compared photobiomodulation therapy with placebo before a 1500 m run in 19 recreationally trained runners in a randomized, double-blind crossover trial. They report no significant overall difference in total run time between treatment and placebo, though 10 participants responded positively to PBMT and responders had higher aerobic capacity than nonresponders. The authors state that PBMT was not able to improve 1500 m performance on average.
- Participants
- 19
- Who or what was studied
- Nineteen recreationally trained runners
- Wavelengths
- 850, 670, 880, 950 nm
- Limits stated in the abstract
- The authors note the trial was conducted in a noncontrolled environment and the responder subgroup was small, with post hoc responsiveness analyses.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on journals.sagepub.com.
Record from PubMed, a service of the National Library of Medicine.
Light parameters mentioned
Found in the title and abstract by pattern. They may be incomplete, so check the paper before comparing studies.
- Wavelength
- 850 nm, 670 nm, 880 nm, 950 nm
- Total energy
- 30 J, 840 J
How to read a trial: what to check before relying on this kind of research.
Terms in this paper: Photobiomodulation therapy, Photobiomodulation, Placebo-controlled, Wavelength, Dose. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.